Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06323434
Other study ID # spice1
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date April 2024
Est. completion date October 2026

Study information

Verified date April 2024
Source University of Freiburg
Contact Katharina Wolf, Dr.
Phone +4976127093556
Email katharina.wolf@uniklinik-freiburg.de
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: Chronic subdural hematoma (cSDH) is a type of intracranial bleeding, predominantly affecting the elderly and males, with an estimated incidence of 8/100.000. The collection of subdural fluid expands slowly, leading eventually to brain tissue compression that results in neurological impairment such as seizures, cognitive decline, and paresis. Most patients need neurosurgical evacuation of the blood to improve and to prevent further, possibly permanent deterioration. Evidently, the cause of such a bleeding must be investigated and if possible treated, or preventive strategies need to be installed if possible. Spinal cerebrospinal fluid (CSF) leaks are a known cause of cSDH but are widely underdiagnosed in this population. The spinal CSF leak causes CSF loss that leads to intracranial hypotension, expansion of intracerebral veins, and traction to the brain and the surrounding tissues. A cSDH is a severe complication of such a leak and occurs in about 30% of all cases with a predominance among the elderly. It is crucial to identify these patients with a spinal leak as treatment pathways differ essentially from patients without a leak. Some smaller studies indicated a prevalence of spinal CSF leaks among cSDH patients of 30% to 80% depending on selection criteria (age, extend of cSDH). Notably, the entity of the CSF-venous fistula, that has been discovered as recent as 9 years ago, and that by now is accounting for 20-25% of all spinal leaks, has not been considered in previous research on cSDH and spinal CSF leaks. Currently, there is no prospective data on spinal CSF leaks in patients with cSDH. Establishment of such data is crucial to improve diagnostic and therapeutic algorithms for spinal CSF leaks in patients with cSDH. Objective: To prospectively assess the prevalence of spinal CSF leaks in patients with cSDH Methods: This is a prospective observational, monocentric study on patients admitted due to cSDH to the Department of Neurosurgery at the Medical Center of the University of Freiburg. Treatment and diagnostic procedures will follow standard protocols. The number of spinal CSF leaks will be assessed to generate the prevalence of spinal CSF leaks in this patient cohort. Furthermore, clinical data, the specific type of the CSF leak, and imaging parameters are assessed systematically to estimate the diagnostic value of these measures.


Description:

Background: Chronic subdural hematoma (cSDH) refers to a blood- and fluid-collection between the brain and the dura that is most common in the elderly with a male predominance. Patients present with headaches, gait instabilities, cognitive impairments, decline of vigilance, hemiparesis, aphasia, or seizures. These symptoms usually lead to hospital admission where the diagnosis can be easily depicted by non-contrast computer tomography (CT), or magnetic resonance imaging (MRI). Image characteristics of the transformed hemoglobin of the blood indicate the chronicity, therefore, the rather slow development of this intracranial hemorrhage. Smaller parts of acute bleeding can attribute to a faster progression. Incidence across all ages is reported at about 8/100.000, while age-depended incidence increases up to 64/100.000 at age of > 79 years. About 2/3 present with unilateral, 1/3 with bilateral hematoma. A symptomatic cSDH requires surgical treatment, which might range from twist drill trepanation with or without drain to open trepanation and fluid evacuation in order to prevent permanent brain damage and further deterioration. Recurrence rates are up to 20%. The mortality rate is increased even after successful treatment of the bleeding. The actual cause for the development of cSDH is yet not sufficiently explored. While a history of minor head trauma is often reported as the leading cause of cSDH, a minor trauma cannot account for the entire pathology in cSDH. Some mechanisms are reported that are rather believed to maintain but not to initiate the process: Characteristic membranes are built that are thought to cause further exudation and hemorrhage. Fragile vessels are discussed to contribute to the process, stimulated by inflammation and poor angiogenesis. Recent efforts to therapeutically address inflammation as a primary target failed, which highlights the critical need of improved therapies. Over the past years, it has become evident, yet widely neglected in clinical daily life, that many cases of cSDH are caused by spinal cerebro spinal fluid (CSF) leaks that lead to spontaneous intracranial hypotension (SIH). These leaks lead to a continuous loss of CSF, which therefore causes hypotension and traction within the skull that is most sever in upright position. This intracranial hypotension can lead to the development of cSDH. If this underlying cause of cSDH is not diagnosed and if it remains untreated, the persistent spinal leak maintains the process of traction and bleeding - leading to a recurrence of the cSDH with a high likelihood and risking further brain damage. Also, there is a risk of further impairment of health and quality of life due to an untreated spinal CSF leak itself (e.g., chronic headache, hearing impairment up to hearing loss, cognitive decline, and superficial siderosis. Unfortunately, spinal CSF leaks are often not investigated, or overseen. The diagnostic sensitivity regarding spinal CSF leaks largely depends on the awareness, experience and dedication of the medical professionals. In an emergency due to intracranial bleeding, a medical history of seemingly fewer threatening symptoms like orthostatic headache or hearing impairment is likely overseen by patients and the medical team, alike. Thus, symptoms and signs are easily missed in cSDH cohorts if not specifically investigated. In patients with atraumatic, bilateral cSDH, it has already become textbook knowledge that investigation for spinal CSF leaks should be conducted. Nevertheless, according to literature, current observations, and expert opinion, a limitation exclusively to bilateral cSDH cannot be justified and sets misdiagnosed patients at risk of further harm. It must be recognized that the mentioned limitation to bilateral cSDH is based on research at times of less sensitive diagnostics without knowledge on the variety of spinal CSF leaks. For example, the discovery of CSF-venous fistulas at the spine has been one of the few genuine new discoveries in Neuroradiology within the past 9 years. By now, within the investigator's cohort, this type of leak accounts for >20% of all leaks and is rather detected in the elderly (mean age 57 years vs. 44 years other leaks, p=0.002), a cohort that is also more likely to develop cSDH. For example: to investigate for CSF-venous fistulas, a conventional prone myelography would lead to a false-negative results, as myelography would need to be performed in lateral decubitus position. Furthermore, another type of a sacral leak has recently been discovered. Therefore, all formerly gathered data on cSDH and SIH need to be interpreted in respect to current developments and the former lack of diagnostic sensitivity. Thus, in experienced SIH centers, it has been established to screen for spinal leaks irrespective of age and size to prevent false treatment and recurrence of cSDH. Literature on spinal CSF leaks in patients with bilateral and unilateral cSDH reports high rates ranging from 26% to even 80 %. The analysis of retrospective data of 216 SIH patients with a proven and surgically treated spinal CSF leak across all ages showed, that 60/216 (30%) had cSDH, with a clear predominance of bilateral (88%) over unilateral (12%) hematomas. Careful management of the bleeding and most importantly closure of the leak led - so far - to no detected recurrence of the cSDH in this cohort. Data also suggest that the development of cSDH is more likely in older SIH patients, which also are more likely to develop CSF-venous fistulas that yet have not been subject of investigation in cSDH cohorts. Also, the intake of oral anticoagulation should not prevent further investigation for spinal CSF leaks, as there is evidence that oral anticoagulation is quite often not the definitive cause of cSDH but rather an additional factor. In summary, cSDH and SIH are interlinked. Older data suggested that only younger patients with cSDH and bilateral cSDH should be suspected to suffer from spinal leaks. In contrast, current data imply that spinal leaks can cause unilateral and bilateral cSDH at any age. On the other hand, there might be a publication bias as with any retrospective studies and prospective data is needed. Aims: Primary aim: a) To estimate the prevalence of spinal CSF leaks in patients with chronic subdural hematoma (cSDH) Secondary aims: 1. To estimate the proportion of different spinal CSF leak types in patients with chronic subdural hematoma (cSDH) 2. To investigate differences in the proportion of spinal CSF leaks and subtypes stratified by age, and stratified by sex 3. To investigate the proportion of interventions needed, delineate clinical parameters, diagnostic findings, resurge need, and differences in outcome in patients with and without proven spinal CSF leak in patients with chronic subdural hematoma (cSDH) 4. To evaluate the diagnostic value of clinical and diagnostic parameters to detect spinal CSF leak in patients with chronic subdural hematoma (cSDH) Methods: The study is monocentric. The design is prospective, longitudinal, and observational. New patients with cSDH admitted to the investigator's department will be screened on a daily basis. The patients, or their caregivers, respectively, will be informed and included upon given written informed consent. As many patients will need emergency evacuation of the subdural hematoma, patients will be specifically asked to consent that data starting at time of admission can be investigated. Diagnostic, treatment, and follow-up procedure will follow clinical standards according to established standard operating procedures (SOP). This standard includes a screening MRI of the brain and spine for signs of spinal CSF leaks. These results in combination with patients' history will be given to the interdisciplinary SIH-Board for consideration. In case of evidence for SIH, further investigation for spinal CSF leaks are initiated. Evidence of SIH can be found in the MRI of the spine as spinal longitudinal epidural collection (SLEC) for some leak types. Further signs indicating a moderate or higher risk of a spinal CSF leaks is a Bern Score of 3 or higher in the MRI of the head. Also, clinical symptoms indicative of spinal CSF leaks, such as orthostatic headache are considered. According to the SOP, the follow-up visits will be scheduled depending on the clinical course that determines the frequencies of visits needed. Follow-ups are conducted at least up to 6 months to scan for resurge of the cSDH and outcome of the procedures, including at least one follow-up visit including imaging after 3 months. This study aims to collect a dataset containing clinical workups up to the 6 months follow-up per participant following standardoperating procedures. Considerations on sample size As this is an explorative, observational study without formal sample size estimation, the study is limited by time of duration (24 months), not by exact numbers. By an estimated population of 1.74 Mio and an incidence of cSDH of 8/100.000, about 140 patients should be expected per year, adding up to approximately 280 patients with cSDH. Considering some patients and/or caregivers who do not consent, a realistic number of 220 to 240 might be achieved. With this sample size, it would be able to estimate the prevalence with a 95% Wilson confidence interval (CI) with a width of 11-13% (for prevalences of 20-80%). For example with a sample size of 220 and a prevalence of 50%, the 95% Wilson CI would be 43.4-56.5%.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 220
Est. completion date October 2026
Est. primary completion date April 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Chronic subdural hematoma on imaging (CT/MRI) 2. Age: 18 years or older 3. Informed consent Exclusion Criteria: 1. General contraindications for MRI examination (e.g., pacemaker wearers, implanted insulin, or pain pump, neurostimulator, etc.) 2. Recurrent chronic subdural hematoma and previously performed diagnostics and treatment in compliance to the current cSDH SOP 3. Severe brain injury, acute subdural hematoma, epidural hematoma, subarachnoid hemorrhage

Study Design


Locations

Country Name City State
Germany University of Freiburg Freiburg Baden-Württemberg

Sponsors (1)

Lead Sponsor Collaborator
University of Freiburg

Country where clinical trial is conducted

Germany, 

References & Publications (22)

Beck J, Gralla J, Fung C, Ulrich CT, Schucht P, Fichtner J, Andereggen L, Gosau M, Hattingen E, Gutbrod K, Z'Graggen WJ, Reinert M, Husler J, Ozdoba C, Raabe A. Spinal cerebrospinal fluid leak as the cause of chronic subdural hematomas in nongeriatric patients. J Neurosurg. 2014 Dec;121(6):1380-7. doi: 10.3171/2014.6.JNS14550. Epub 2014 Jul 18. — View Citation

Dobrocky T, Grunder L, Breiding PS, Branca M, Limacher A, Mosimann PJ, Mordasini P, Zibold F, Haeni L, Jesse CM, Fung C, Raabe A, Ulrich CT, Gralla J, Beck J, Piechowiak EI. Assessing Spinal Cerebrospinal Fluid Leaks in Spontaneous Intracranial Hypotension With a Scoring System Based on Brain Magnetic Resonance Imaging Findings. JAMA Neurol. 2019 May 1;76(5):580-587. doi: 10.1001/jamaneurol.2018.4921. — View Citation

Dumont TM, Rughani AI, Goeckes T, Tranmer BI. Chronic subdural hematoma: a sentinel health event. World Neurosurg. 2013 Dec;80(6):889-92. doi: 10.1016/j.wneu.2012.06.026. Epub 2012 Jun 19. — View Citation

Edlmann E, Giorgi-Coll S, Whitfield PC, Carpenter KLH, Hutchinson PJ. Pathophysiology of chronic subdural haematoma: inflammation, angiogenesis and implications for pharmacotherapy. J Neuroinflammation. 2017 May 30;14(1):108. doi: 10.1186/s12974-017-0881-y. — View Citation

El Rahal A, Beck J, Ahlborn P, Bernasconi C, Marbacher S, Wanderer S, Burkhardt JK, Daniel RT, Ferrari A, Hausmann O, Kamenova M, Kothbauer K, Lutz K, Mariani L, Alfieri A, Schoni D, Schucht P, Raabe A, Regli L, Kuhlen D, Seule M, Soleman J, Starnoni D, Zaldivar J, Zweifel C, Schaller K, Fung C. Incidence, therapy, and outcome in the management of chronic subdural hematoma in Switzerland: a population-based multicenter cohort study. Front Neurol. 2023 Sep 14;14:1206996. doi: 10.3389/fneur.2023.1206996. eCollection 2023. — View Citation

Feghali J, Yang W, Huang J. Updates in Chronic Subdural Hematoma: Epidemiology, Etiology, Pathogenesis, Treatment, and Outcome. World Neurosurg. 2020 Sep;141:339-345. doi: 10.1016/j.wneu.2020.06.140. Epub 2020 Jun 25. — View Citation

Hamou HA, Clusmann H, Schulz JB, Wiesmann M, Altiok E, Hollig A. Chronic Subdural Hematoma. Dtsch Arztebl Int. 2022 Mar 25;119(12):208-213. doi: 10.3238/arztebl.m2022.0144. — View Citation

Hufschmidt, A., S. Rauer, F. Glocker, and Hrsg, eds. 2022. Neurologie compact. Stuttgart: Thieme und doi:10.1055/b000000096

Kim HJ, Lee JW, Lee E, Kang Y, Ahn JM. Incidence of Spinal CSF Leakage on CT Myelography in Patients with Nontraumatic Intracranial Subdural Hematoma. Diagnostics (Basel). 2021 Dec 6;11(12):2278. doi: 10.3390/diagnostics11122278. — View Citation

Kranz PG, Malinzak MD, Gray L, Willhite J, Amrhein TJ. Resisted Inspiration Improves Visualization of CSF-Venous Fistulas in Spontaneous Intracranial Hypotension. AJNR Am J Neuroradiol. 2023 Aug;44(8):994-998. doi: 10.3174/ajnr.A7927. Epub 2023 Jul 6. — View Citation

Lutzen N, Aleman EB, El Rahal A, Volz F, Fung C, Beck J, Urbach H. Sacral Dural Tears as a Cause of Spontaneous Intracranial Hypotension. Clin Neuroradiol. 2023 Dec;33(4):957-964. doi: 10.1007/s00062-023-01292-0. Epub 2023 Jun 1. — View Citation

Lutzen N, Beck J, Urbach H. Cerebrospinal Fluid Venous Fistula Imaging with Ultrahigh-Resolution Cone-Beam Computed Tomography. JAMA Neurol. 2023 Aug 1;80(8):870-871. doi: 10.1001/jamaneurol.2023.1640. — View Citation

Mehta V, Harward SC, Sankey EW, Nayar G, Codd PJ. Evidence based diagnosis and management of chronic subdural hematoma: A review of the literature. J Clin Neurosci. 2018 Apr;50:7-15. doi: 10.1016/j.jocn.2018.01.050. Epub 2018 Feb 7. — View Citation

Miah IP, Holl DC, Blaauw J, Lingsma HF, den Hertog HM, Jacobs B, Kruyt ND, van der Naalt J, Polinder S, Groen RJM, Kho KH, van Kooten F, Dirven CMF, Peul WC, Jellema K, Dammers R, van der Gaag NA; DECSA Collaborators. Dexamethasone versus Surgery for Chronic Subdural Hematoma. N Engl J Med. 2023 Jun 15;388(24):2230-2240. doi: 10.1056/NEJMoa2216767. — View Citation

Miranda LB, Braxton E, Hobbs J, Quigley MR. Chronic subdural hematoma in the elderly: not a benign disease. J Neurosurg. 2011 Jan;114(1):72-6. doi: 10.3171/2010.8.JNS10298. Epub 2010 Sep 24. — View Citation

Sahyouni R, Goshtasbi K, Mahmoodi A, Tran DK, Chen JW. Chronic Subdural Hematoma: A Historical and Clinical Perspective. World Neurosurg. 2017 Dec;108:948-953. doi: 10.1016/j.wneu.2017.09.064. Epub 2017 Sep 19. — View Citation

Schievink WI, Maya MM, Barnard ZR, Moser FG, Jean-Pierre S, Waxman AD, Nuno M. Behavioral Variant Frontotemporal Dementia as a Serious Complication of Spontaneous Intracranial Hypotension. Oper Neurosurg (Hagerstown). 2018 Nov 1;15(5):505-515. doi: 10.1093/ons/opy029. — View Citation

Schievink WI, Maya MM, Harris J, Galvan J, Tache RB, Nuno M. Infratentorial Superficial Siderosis and Spontaneous Intracranial Hypotension. Ann Neurol. 2023 Jan;93(1):64-75. doi: 10.1002/ana.26521. Epub 2022 Oct 22. — View Citation

Schievink WI, Maya MM, Pikul BK, Louy C. Spontaneous spinal cerebrospinal fluid leaks as the cause of subdural hematomas in elderly patients on anticoagulation. J Neurosurg. 2010 Feb;112(2):295-9. doi: 10.3171/2008.10.JNS08428. — View Citation

Schievink WI, Moser FG, Maya MM. CSF-venous fistula in spontaneous intracranial hypotension. Neurology. 2014 Jul 29;83(5):472-3. doi: 10.1212/WNL.0000000000000639. Epub 2014 Jun 20. No abstract available. — View Citation

Takahashi K, Mima T, Akiba Y. Chronic Subdural Hematoma Associated with Spontaneous Intracranial Hypotension: Therapeutic Strategies and Outcomes of 55 Cases. Neurol Med Chir (Tokyo). 2016;56(2):69-76. doi: 10.2176/nmc.oa.2015-0032. Epub 2015 Oct 21. — View Citation

Yang W, Huang J. Chronic Subdural Hematoma: Epidemiology and Natural History. Neurosurg Clin N Am. 2017 Apr;28(2):205-210. doi: 10.1016/j.nec.2016.11.002. Epub 2017 Feb 1. — View Citation

* Note: There are 22 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary evidence of a spinal CSF leak (yes/no) The primary endpoint is evidence of a spinal CSF leak (yes/no) in patients with chronic subdural hematoma (cSDH) depicted by MRI: evidence spinal longitudinal extradural fluid (SLEC), or Myelogram: detection of spinal CSF leak up to 4 weeks
Secondary Number of identified CSF leak types: Ventral leak
Lateral leak
CSF-venous fistula
Sacral leak
Undefined
up to 4 weeks
Secondary Number of diagnostic procedures performed: CT head
MRI head
MRI spine
Myelography
up to 6 month
Secondary Number, and site of interventions needed for cSDH: Twist drill trephination
Twist drill trephination with drain
Conventional trepanation
Twist drill trephination or conventional trepanation with drain and any form of controlled lavage (saline and or clot lysis)
Embolisation of media meningeal artery
up to 6 month
Secondary Color of hematoma evacuated: clear to amber-colored (yes/no)
"motor-oil" appearance (yes/no)
up to 6 month
Secondary Age in years at time of inclusion
Secondary body height height (m) at time of inclusion
Secondary body weight weight (kg) Body mass index derived by height and weight (kg/m2) at time of inclusion
Secondary Body mass index (BMI) derived by height and weight (kg/m2) at time of inclusion
Secondary sex male
female
diverse
at time of inclusion
Secondary Karnofsky Index Range: 0-100%, 100% indicating best health up to 6 months
Secondary Anti-platelet therapy intake yes
no
up to 6 months
Secondary Anticoagulation intake yes
no
up to 6 months
Secondary Blood pressure medication intake yes
no
up to 6 months
Secondary Lipid regulation medication intake yes
no
up to 6 months
Secondary Hormonal regulation medication intake yes
no
up to 6 months
Secondary Immunotherapeutic medication intake yes
no
up to 6 months
Secondary other medication intake yes
no
up to 6 months
Secondary history of trauma No trauma,
recent trauma within 0-4 weeks,
past trauma >4 weeks ago
up to 6 months
Secondary national institutes of health stroke scale (NIHSS) range 0 to 42, 0 indicating no neurological deficits up to 6 months
Secondary gait disorder yes
no
up to 6 months
Secondary Modified Rankin Scale (mRS) range 0-6, 0 indicating best health up to 6 months
Secondary Headache-Impact-Test (HIT)-6 - Headache-Impact-Test (HIT)-6 range 36 to 78 points, 78 indicating highest impact of headaches up to 6 months
Secondary current working capacity, range 0 to 5, 0 indicating full capacity up to 6 months
Secondary complaints current complaints (descriptively)
most stressful complaint (descriptively)
up to 6 months
Secondary headache severity range 0 to 10, 10 indicating most severe pain up to 6 months
Secondary Days within the last month with headaches
with pain medication intake in the last month
up to 6 months
Secondary maximum duration being continuously upright in hours up to 6 months
Secondary severeness of dizziness - in 0 to 10, 10 being most severe up to 6 months
Secondary Severeness of shoulder- and neck pain - in 0 to 10, 10 being most severe up to 6 months
Secondary severeness of nausea - in 0 to 10, 10 being most severe up to 6 months
Secondary severeness of hearing disturbances and tinnitus - in 0 to 10, 10 being most severe up to 6 months
Secondary severeness of cognitive deficits - in 0 to 10, 10 being most severe up to 6 months
Secondary severeness of visual disturbances - in 0 to 10, 10 being most severe up to 6 months
Secondary exhaustion -rated between 0 to 5, with 5 indicating highest burden up to 6 months
Secondary ability to focus and concentrate rated between 0 to 5, with 5 indicating highest burden up to 6 months
Secondary Patient's Global Impression of Change (PGIC) Patient's Global Impression of Change (PGIC), range 7 to 42, 7 indicating highest improvements up to 6 months
Secondary Self-Administered Comorbidity Questionnaire (SCQ) - 13-item Self-Administered Comorbidity Questionnaire (SCQ), range 0 to 39, 0 indicating lowest burden up to 6 months
Secondary 5 dimension / 5 levels European Quality of life questionnaire (EQ-5D-5L) Index <0 to 1, 1 indicating unimpaired health up to 6 months
Secondary 5 dimension / 5 levels European Quality of life questionnaire (EQ-5D-5L) visual analogue scale 0 to 100, with 100 indicating unimpaired wellbeing up to 6 months
Secondary Hematocrit in% up to 2 days
Secondary Size of the chronic subdural hematoma mm^3 up to 6 month
Secondary Volumetry of the cranial compartments mm^3 up to 6 month
Secondary Bern-Score according to Dobrocky et al ange 0 to 9 with 9 indicating highest likelihood of a spinal CSF leak
Spinal longitudinal extradural fluid collection (SLEC)(yes/no)
DiverTICula (TIC) (yes/no)
up to 6 month
Secondary Spinal longitudinal extradural fluid collection (SLEC) yes
no
up to 6 month
Secondary DiverTICula (TIC) yes
no
up to 6 month
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06347796 - Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study N/A
Recruiting NCT04065113 - Middle Meningeal Artery Embolization for Chronic Subdural Hematoma N/A
Recruiting NCT02938468 - Mgt of Chronic Subdural Hematoma Using Dexamethasone Phase 2/Phase 3
Completed NCT03307395 - Middle Meningeal Artery Embolization for Treatment of Chronic Subdural Hematoma N/A
Terminated NCT04502745 - A Study to Evaluate Endoscope-assisted, Minimally-invasive Cortical Access System for Chronic Subdural Evacuation N/A
Terminated NCT03353259 - Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery Phase 2/Phase 3
Recruiting NCT02568124 - Tranexamic Acid in Chronic Subdural Hematomas Phase 2/Phase 3
Completed NCT02282228 - Detecting Chronic Subdural Hematoma With Microwave Technology N/A
Recruiting NCT05143216 - High Concentration Oxygen Therapy for Pneumocephalus in Chronic Subdural Haematoma: A Prospective Observational Study
Active, not recruiting NCT04816591 - Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA N/A
Recruiting NCT06401772 - The Effectiveness and Safety of Body Posture in Preventing Postoperative Recurrence for Chronic Subdural Hematoma N/A
Completed NCT06134206 - Burr Hole Ultrasound Study N/A
Recruiting NCT03666949 - General Anesthesia Versus Locoregional Anesthesia for Evacuation of Chronic Subdural Hematoma N/A
Recruiting NCT03280212 - Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma Phase 3
Completed NCT03447327 - Outcome of Single Burr Hole Under Local Anaesthesia in the Management of Chronic Subdural Hematoma N/A
Recruiting NCT05374681 - Efficacy of a Minimally Invasive Therapy Adjuvant to the Standards of Care by Cyanoacrylate Embolization N/A
Recruiting NCT05267184 - Swedish Trial on Embolization of Middle Meningeal Artery Versus Surgical Evacuation in Chronic Subdural Hematoma N/A
Not yet recruiting NCT05900557 - Neurologic Deficits and Recovery in Chronic Subdural Hematoma N/A
Completed NCT02757235 - The Swedish Study of Irrigation Fluid Temperature in the Evacuation of Chronic Subdural Hematoma N/A
Terminated NCT02111785 - Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma Phase 2/Phase 3